Studies

2011

Bertuccio P, La Vecchia C, Silverman DT, Petersen GM, Bracci PM, Negri E, Li D, Risch HA, Olson SH, Gallinger S, Miller AB, Bueno-de-Mesquita HB, Talamini R, Polesel J, Ghadirian P, Baghurst PA, Zatonski W, Fontham ET, Bamlet WR, Holly EA, Lucenteforte E, Hassan M, Yu H, Kurtz RC, Cotterchio M, Su J, Maisonneuve P, Duell EJ, Bosetti C, Boffetta P.
Cigar and pipe smoking, smokeless tobacco use and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (PanC4).
Ann Oncol. 2011 Jan 18. [Epub ahead of print]

Naufal ZS, Marano KM, Kathman SJ, Wilson CL.
Differential exposure biomarker levels among cigarette smokers and smokeless tobacco consumers in the National Health and Nutrition Examination Survey 1999-2008.
Biomarkers. 2011 Feb 25. [Epub ahead of print]

O’Connor RJ, Norton KJ, Bansal-Travers M, Mahoney MC, Cummings KM, Borland R.
US smokers’ reactions to a brief trial of oral nicotine products.
Harm Reduct J. 2011 Jan 10;8(1):1.

2010

Blank MD, Eissenberg T.
Evaluating oral noncombustible potential-reduced exposure products for smokers.
Nicotine Tob Res. 2010 Apr;12(4):336-43. Epub 2010 Feb 16.

Carpenter MJ, Gray KM.
A pilot randomized study of smokeless tobacco use among smokers not interested in quitting: changes in smoking behavior and readiness to quit.
Nicotine Tob Res. 2010 Feb;12(2):136-43. Epub 2010 Jan 6.

Cobb CO, Weaver MF, Eissenberg T.
Evaluating the acute effects of oral, non-combustible potential reduced exposure products marketed to smokers.
Tob Control. 2010 Oct;19(5):367-73. Epub 2009 Apr 2.

Hecht SS, Stepanov I, Hatsukami DK.
Major tobacco companies have technology to reduce carcinogen levels but do not apply it to popular smokeless tobacco products.
Tob Control. 2010 Oct 7. [Epub ahead of print] No abstract available.

2009

Parascandola M, Augustson E, O’Connell ME, Marcus S.
Consumer awareness and attitudes related to new potential reduced-exposure tobacco product brands.
Nicotine Tob Res. 2009 Jul;11(7):886-95. Epub 2009 Jun 18.

2008

Ending tobacco smoking in Britain Radical strategies for prevention and harm reduction in nicotine addiction.
A report by the Tobacco Advisory Group of the Royal College of Physicians, September 2008

Blank MD, Sams C, Weaver MF, Eissenberg T.
Nicotine delivery, cardiovascular profile, and subjective effects of an oral tobacco product for smokers.
Nicotine Tob Res. 2008 Mar;10(3):417-21.

Slater S, Giovino G, Chaloupka F.
Surveillance of tobacco industry retail marketing activities of reduced harm products.
Nicotine Tob Res. 2008 Jan;10(1):187-93.

2007

Kotlyar M, Mendoza-Baumgart MI, Li ZZ, Pentel PR, Barnett BC, Feuer RM, Smith EA, Hatsukami DK.
Nicotine pharmacokinetics and subjective effects of three potential reduced exposure products, moist snuff and nicotine lozenge.
Tob Control. 2007 Apr;16(2):138-42.

Mendoza-Baumgart MI, Tulunay OE, Hecht SS, Zhang Y, Murphy S, Le C, Jensen J, Hatsukami DK.
Pilot study on lower nitrosamine smokeless tobacco products compared with medicinal nicotine.
Nicotine Tob Res. 2007 Dec;9(12):1309-23.

O’Hegarty M, Richter P, Pederson LL.
What do adult smokers think about ads and promotional materials for PREPs?
Am J Health Behav. 2007 Sep-Oct;31(5):526-34.

2006

Caraballo RS, Pederson LL, Gupta N.
New tobacco products: do smokers like them?
Tob Control. 2006 Feb;15(1):39-44.

Levy DT, Mumford EA, Cummings KM, Gilpin EA, Giovino GA, Hyland A et al.
The potential impact of a low-nitrosamine smokeless tobacco product on cigarette smoking in the United States: Estimates of a panel of experts.
Addict Behav. 2006 Jul;31(7):1190-200.

Martinet Y, Bohadana A, Fagerstrom K.
Would alternate tobacco products use be better than smoking?
Lung Cancer 2006.

MMWR.
Use of Cigarettes and Other Tobacco Products Among Students Aged 13–15 Years – Worldwide
1999-2005. May 26, 2006 / 55(20);553-56

Nilsson R.
Possible carcinogenicity of smokeless tobacco
Int.J Cancer 2006;118(6):1582-3.

Phillips CV, Guenzel B, Bergen P.
Deconstructing anti-harm-reduction metaphors; mortality risk from falls and other traumatic injuries compared to smokeless tobacco use.
Harm.Reduct.J 2006;3(1):15.

Ramström LM, Foulds J.
Role of snus in initiation and cessation of tobacco smoking in Sweden.
Tob.Control 2006;15(3):210-4.

Stepanov I, Jensen J, Hatsukami D, Hecht SS.
Tobacco-specific nitrosamines in new tobacco products.
Nicotine Tob Res. 2006 Apr;8(2):309-13.

2005

Accortt NA, Waterbor JW, Beall C, Howard G.
Cancer incidence among a cohort of smokeless tobacco users (United States). Cancer Causes Control 2005;16(9):1107-15

Bunch R, Thomas M, Bunch N.
Smokeless tobacco for a nicotine-dependent schizoaffective patient.
Am.J Psychiatry 2005;162(8):1543-4.

Fagerstrom K.
The nicotine market: an attempt to estimate the nicotine intake from various sources and the total nicotine consumption in some countries.
Nicotine.Tob.Res. 2005;7(3):343-50.

Godtfredsen NS, Prescott E, Osler M.
Effect of smoking reduction on lung cancer risk.
JAMA 2005;294(12):1505-10.

Hergens MP, Ahlbom A, Andersson T, Pershagen G.
Swedish moist snuff and myocardial infarction among men.
Epidemiology 2005;16(1):12-6.

O’Connor RJ, Hyland A, Giovino GA, Fong GT, Cummings KM.
Smoker awareness of and beliefs about supposedly less-harmful tobacco products.
Am.J Prev.Med. 2005;29(2):85-90.

O’Connor RJ, Kozlowski LT, Flaherty BP, Edwards BQ.
Most smokeless tobacco use does not cause cigarette smoking: results from the 2000 National Household Survey on Drug Abuse.
Addict.Behav. 2005;30(2):325-36.

O’Reilly EJ, McCullough ML, Chao A, Henley SJ, Calle EE, Thun MJ et al.
Smokeless tobacco use and the risk of Parkinson’s disease mortality
Mov Disord. 2005;20(10):1383-4.

Rodu B, Cole P.
Smokeless tobacco and periodontal disease
J Dent.Res. 2005;84(12):1086-7.

Rodu B, Nasic S, Cole P.
Tobacco use among Swedish schoolchildren.
Tob.Control 2005;14(6):405-8.

Rosenquist K, Wennerberg J, Schildt EB, Bladstrom A, Hansson BG, Andersson G.
Use of Swedish moist snuff, smoking and alcohol consumption in the aetiology of oral and oropharyngeal squamous cell carcinoma. A population-based case-control study in southern Sweden.
Acta Otolaryngol. 2005;125(9):991-8.

Roth HD, Roth AB,Liu X.
Health risks of smoking compared to Swedish snus.
Inhal.Toxicol. 2005;17(13):741-8.

Schneider NG, Terrace S, Koury MA, Patel S, Vaghaiwalla B, Pendergrass R et al.
Comparison of three nicotine treatments: initial reactions and preferences with guided use
Psychopharmacology (Berl) 2005;182(4):545-50

Stegmayr B, Eliasson M, Rodu B.
The decline of smoking in northern Sweden.
Scand.J Public Health 2005;33(4):321-4.

Stepanov I, Jensen J, Hatsukami D, Hecht SS.
Tobacco-specific nitrosamines in new tobacco products
Nicotine.Tob.Res. 2005;8(2):309-13.

Warner KE.
Will the next generation of “safer” cigarettes be safer?
J Pediatr.Hematol.Oncol. 2005;27(10):543-50.

2004

Heath J, Andrews J, Balkstra CR.
Potential reduction exposure products and FDA tobacco and regulation: a CNS call to action.
Clin Nurse Spec. 2004 Jan-Feb;18(1):40-8; quiz 49-50. Review.

Gray N.
The ethics of policies for the prevention of tobacco disease.
Acta Oncol. 2004;43(1):8-10.

Levy DT, Mumford EA, Cummings KM, Gilpin EA, Giovino G, Hyland A et al.
The relative risks of a low-nitrosamine smokeless tobacco product compared with smoking cigarettes: estimates of a panel of experts.
Cancer Epidemiol.Biomarkers Prev. 2004;13(12):2035-42.

McNeill A.
Harm reduction.
BMJ 2004;328(7444):885-7.

Rodu B, Jansson C.
Smokeless tobacco and oral cancer: a review of the risks and determinants.
Crit Rev.Oral Biol.Med. 2004;15(5):252-63.